PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Nutrition disorder

Drugs in development · updated 30 October 2026

Nutrition disorder: drugs in development

As of 30 October 2026 there are 8 active clinical trials (recruiting or ongoing, phases I–III) on 10 drugs for nutrition disorder. 5 are experimental, that is not yet approved in the United States.

8Active trials
5Experimental drugs
3Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
PF-08653944III3NCT07595549
BerobenatideIII1NCT07845500
StarchIII1NCT06500234
PF-08653945II1NCT07575932
MBX 4291I1NCT07142707

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
TirzepatideZepbound, MounjaroIII2NCT07845500
Megestrol AcetateMegace Es®, Megace®III1NCT06500234
OlanzapineWeltruza®, Zyprexa Relprevv®III1NCT06500234
OrforglipronFoundayo®III1NCT07153471
SemaglutideWegovy, RybelsusIII1NCT07845500

Sorted by most advanced phase and number of active trials.

All 10 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D009748 “Nutrition Disorders”.

ItalianoFrançaisDeutsch